Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, brexanolone (SAGE-547), is in Phase 3 clinical development for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders.
Oct 23, 2018
Copyright Nasdaq. Minimum 15 minutes delayed.
Copyright West LLC. Minimum 15 minutes delayed.
Events & Presentations
Nov 6, 2018 at 8:00 AM EST
Sage Therapeutics Q3 2018 Financial Results Conference Call
Sep 12, 2018 at 1:40 PM EDT
Morgan Stanley 16th Annual Global Healthcare Conference
Aug 8, 2018 at 11:00 AM EDT
Canaccord Genuity 38th Annual Growth Conference